

VIRTUAL INVESTOR SUMMIT 2023

EXPLORE | INVEST | GROW
26-27 October



emyria
(ASX:EMD)



*Creating tomorrow's therapies
from today's patient stories*

Investor Summit
27 October 2023 | mwinlo@emyria.com

DISCLAIMER to presentation

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Presentation release authorised by Michael Winlo, CEO and Managing Director

EMYRIA | CORPORATE STRUCTURE


KEY METRICS	VALUE
Market Capitalisation	~A\$25.5M
Shares on Issue	349,226,509
Last reported cash (at 30 Sep 2023)	A\$2.14M

Emyria overview

Understand how your share registry has changed over time.

Past 90 days

☒ Volume ☒ Shareholder count ☒ Share price ☒ Announcements





emyria

Integrated **drug development** & **clinical services** company
focussed on mental health, neuropsychiatry, and certain
neurological conditions

OUR OPPORTUNITY | THE RISING COST AND BURDEN OF MENTAL HEALTH CARE

Growing Mental Health Burden

\$225 Billion

Annual US Spending (2019) ¹

1 in 3 Australian
psychologists have
closed books ²

Emerging Therapies Show Promise

Example:

Psychedelic-assisted therapies:

~80+%

of PTSD patients on
MDMA-assisted therapy had
**clinically significant
improvement** ^{3, 4}




Australia 1st to Legalise; 1 yr Headstart

[Home](#) > [News and Community](#) > [Media releases](#)

Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists

Published: 3 February 2023

[Listen](#) [Print](#) [Share](#)



From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxymethamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.

SOURCES:

1. <https://www.behavr.com/mental-wellness>

2. <https://psychology.org.au/for-members/news-and-updates/news/2022/australians-need-psychological-help-more-than-ever>

3. Mitchell, J.M., et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27, 1025–1033 (2021)

4. Mitchell, J.M., et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med (2023). <https://doi.org/10.1038/s41591-023-02565-4>

5. <https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin>

MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

WHAT IS POST-TRAUMATIC STRESS DISORDER (PTSD)? ¹

A chronic, debilitating mental health disorder that can occur following a traumatic event

Symptoms

Re-experiencing:

Intrusive memories, flashbacks, and nightmares

Avoidance:

Evading reminders of the trauma and feeling detached

Increased arousal:

Irritability, sleep issues, and easily startled

Mood & cognition:

Persistent negative emotions and distorted blame

Physical symptoms:

Palpitations, sweating, and gastrointestinal issues

Current Treatments



COUNSELLING & PSYCHOTHERAPY



PRESCRIPTION DRUGS



EXPOSURE THERAPY

Re-imagining events in a safe environment




GROUP THERAPY

Affects ~1m Australians
with **High Rates of**
Resistance

up to **50%**
treatment resistance ²

UNIQUE PSYCHO- PHARMACOLOGICAL EFFECTS OF MDMA (“ecstasy”)



INCREASED

- feelings of wellbeing
- sociability and extroversion
- interpersonal trust

AN ALERT STATE OF CONSCIOUSNESS

DECREASED



- feelings of fear & defensiveness



These effects suggest MDMA could be a promising **adjunct to psychotherapy** for a range of challenging MENTAL HEALTH CONDITIONS.



MDMA-AT SHOWING REMARKABLE PROMISE FOR PTSD | TWO PHASE 3 TRIALS COMPLETED^{1,2}

Improves symptoms



MDMA-AT significantly attenuated PTSD symptomology, as shown by the change in CAPS-5 total severity score from baseline to 18 weeks after baseline

Improves function



MDMA-AT significantly reduced clinician-rated functional impairment, implying an improved quality of life, as shown by the change in Sheehan Disability Scale score from baseline to 18 weeks after baseline

Key benefits after 3 treatment sessions

86.5% of MDMA-AT participants reported improvement, compared to 69% in the placebo group.

71.2% of MDMA-AT participants no longer met PTSD criteria, compared to 47.6% in the placebo group.

Enhancements reported in various life areas, including familial, social, and professional aspects.

THE PROBLEM:

Very few clinical services are capable of delivering these therapies.

& We *need* more **evidence**.

*“For approval to prescribe, psychiatrists will need to demonstrate: **appropriate training, patient selection, evidence-based treatment protocols and patient monitoring.***

*Further, ongoing **psychotherapeutic support** remains an essential component of the psychedelic treatment model.”*

-RANZCP (College of Psychiatrists) ¹






Emyria has done this *before....*

& has been preparing for years


EMYRIA CLINICS | ALREADY DELIVERING MDMA-AT IN A CLINICAL TRIAL ¹

Assessing feasibility and cost-benefits to support payer engagement



HOW LARGE IS THE OPPORTUNITY?

35% of Australian adults experienced at least 1 mental health challenge in the last 12 months ¹



emyria

SOURCES:
1. <https://www.abs.gov.au/statistics/health/mental-health/national-study-mental-health-and-wellbeing/latest-release#key-statistics>
2. See ASX presentation 06 September 2023

Market for MDMA-AT for PTSD ²

Total Addressable Market (TAM)
In any 12 month period, PTSD affects 6% of Australian adults
~1,000,000 (much greater globally)

↓
Serviceable Addressable Market (SAM)
50% of sufferers have treatment chronic/severe PTSD; ~22% not suitable
Eligible for MDMA-AT ~400,000

↓
Early Target Market
1-10% of patients suitable for MDMA-AT in Western Australia:
~300 to 3,000 patients

At ~\$30k/pt for treatment, opportunity for patient impact and a revenue stream to support growth

EMYRIA'S MODEL FOR IMPACT & GROWTH

1. Create *Immediate* Impact



Multidisciplinary clinics providing **best-in-class** and **emerging** treatments

Today we've cared for over 15,000 patients and are generating over \$1m/quarter¹

2. Scale



Add **new services** and grow via **strategic partnerships**

Initiate promising new services (eg. MDMA-assisted therapy) and form strategic partnerships²

3. Create *Long-term* Impact & Value






Use our **proprietary data** to improve our **care models** and develop **new drug treatments**

We've built a large library of novel MDMA analogues & developed Ultra-Pure CBD dose forms³

1. IMMEDIATE IMPACT & SCALE | EMYRIA CLINICS

We've provided care for over 15,000 patients and are delivering strong billings growth (250%+ last quarter¹)



- **Physical clinics & telehealth**
- **40+** clinical conditions
- **25+** clinicians (psychiatrists, GPs, mental health nurses, physical, social and occupational therapists, counsellors)
- Ethics-approved **MDMA-AT trial**
- **World's largest data registry** on cannabinoid-based therapies and outcomes¹ leveraging 

2. LEVERAGING OUR DATA FOR CARE MODEL & DRUG DEVELOPMENT

PROGRAM	DEVELOPMENT GOAL	STAGE	COMMERCIAL STATUS	CATEGORY LEADER
Ultra-Pure CBD Capsules <i>Highly bioavailable CBD</i>				
EMD-RX5	Pharmacy treatment for mild anxiety & stress	Phase 3 clinical trials	Partnered with ASPEN PHARMACARE AUSTRALIA ¹	N/A
EMD-RX7/9	Prescription medicines for complex pain & anxiety	Preparing Phase 1 & Pre-IND Partnered with NIH ²	Pursuing partners	Epidiolex (\$1B/yr) ³
Novel, MDMA-Inspired Medicines <i>Developed with the University of Western Australia</i>				
EMD-MX1	Faster-acting MDMA to reduce therapy times			Kinosis (Preclinical offer \$273M) ⁴
EMD-MX2	Adjunct treatment for Parkinson's disease	Preclinical screening	Pursuing partners	Levodopa (\$8B /yr) ⁵
EMD-MX3	Other non-neurological indications			Ofev (\$5B/yr) ⁶
Medicine-Assisted Care Programs				
MDMA-AT	MDMA-assisted therapy for PTSD	Actively treating	Developing models to support other partner sites	MAPS (raised US\$140M to date) ⁷
Ketamine & Psilocybin-AT	Ketamine and Psilocybin-assisted therapy for depression	Care models in development		Compass Pathways (Market Cap \$560M) ⁸

SOURCES:

1. See ASX release 04 April 2023

2. See ASX release 28 Nov 2022

3.

<https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2023>


4. <https://www.sydney.edu.au/news-opinion/news/2023/05/05/sydney-spinout-kinosis-273m-develop-drugs-psychiatric-disorders.html>

5. <https://www.gminsights.com/pressrelease/parkinsons-disease-therapeutics-market>

6. <https://www.boehringer-ingelheim.com>

7. <https://www.lucid.news/strategy-maps-turns-equity-investment/>

8. <https://finance.yahoo.com/quote/CMPS/>



We've developed multiple dose forms targeting registration as capsule medicines

EMD-RX5



An Ultra-Pure CBD capsule for **over-the-counter** treatment of anxiety and stress symptoms.

15% of all adults.¹

In **Phase 3** clinical trials.

Commercialised to Aspen Pharmacare Australia.²

EMD-RX7



High bioavailability Ultra-Pure CBD for **prescription** indications, like opioid-sparing.

Opioid use disorder is a **\$471.0 billion** expense in the US.³

In preclinical screening in USA.

Currently being assessed by the **NIH (USA)** in their Preclinical Screening Program for Pain (PSPP) program.⁴

EMD-RX9



High potency, high bioavailability Ultra-Pure CBD for **prescription** indications.⁵

Market leader: **Epidiolex (\$1B/yr)**⁶

Preparing for Phase 1 clinical trials.

Seeking commercialisation partners.

SOURCES:

1. Australian Institute of Health and Welfare 2018. Australia's health 2018. Australia's health series no. 16. AUS 221.

2. See ASX release 04 April 2023

3. <https://www.cdc.gov/injury/features/health-econ-cost-of-injury/index.html>


4. See ASX release 28 Nov 2022

5. See ASX release 24 April 2023

6. <https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2022>


EMYRIA DRUG DEVELOPMENT | MDMA-ANALOGUES

One of the **world's largest libraries of MDMA analogues** developed with  THE UNIVERSITY OF WESTERN AUSTRALIA



EMD-MX1


Increasing versatility of drug-assisted therapy for mental health disorders



We have created MDMA-like molecules with rapid *and* extended half-lives.

EMD-MX2


Selective serotonin & dopamine releasers to help symptoms of L-DOPA induced dyskinesia (LID)



LID affects up to 80% of all Parkinson's disease sufferers.


EMD-MX3

Highly specific transporter binding molecules for range of indications.



We have novel molecules that are potent antagonists of 5HT2B, involved in fibrosis.

EMYRIA'S UNIQUE MODEL | SHORT-TERM IMPACT & LONG-TERM VALUE CREATION



LEADERS IN CARE DELIVERY, DATA and DRUG DEVELOPMENT



CHAIRMAN

Dr Stewart Washer
PhD (Microbiology)
Serial entrepreneur
Multiple ASX listings



NE-DIRECTOR

Prof Sir John Tooke
FRCP, FMedSci
Clinician-researcher
Expert in learning health
systems



E-DIRECTOR

Dr Karen Smith
MD, PhD, MBA, LLM
US-based biopharma
executive. Multiple FDA
approvals



MANAGING DIRECTOR

Dr Michael Winlo
MBBS(Hons), MBA
Entrepreneur, big data,
clinical trials and
drug development



NE-DIRECTOR

Dr Mohit Kaushal
Technology enabled
clinical services,
strategy and
investment



MEDICAL DIRECTOR

C/Prof Alistair Vickery
MBBS, FRACGP, FCHSM
Medical Director
Epidemiological researcher

CLINICAL & SCIENTIFIC LEADERSHIP



Claire Kullak
BSc (Nursing)

Trauma-specialist and
nationally recognised
trainer



Dr Jon Laugharne
**MBBS, FRCP (UK),
FRANZCP**

Consultant psychiatrist &
therapist



Dr Jenny Morgan
MBBS, FRANZCA

Consultant pain specialist



Prof Matt Piggott
BSc, PhD (Chemistry)

Specialist in amphetamine
chemistry and novel
drug design



Dr David Gunn
MBBS, FRACGP

Cannabinoid expert
Substance abuse &
mental health
treatment



Dr Jeremy Tannenbaum
BSc, MBBS (Hons), FRANZCP

Consultant Pain Specialist
Consultant Psychiatrist





Jazz Pharmaceuticals



linear



emyria — OUR ROADMAP

#	PROGRAM	MILESTONE 1	MILESTONE 2	MILESTONE 3	OTHERS
1	Deliver MDMA-AT	Begin MDMA-AT treatment 	Emyria psychiatrists obtain Authorised Prescriber status	Complete patient recruitment for Phase 2b trial (MDMA)	Complete Phase 2b trial for MDMA
2	Develop Novel MDMA Treatments	Animal study results for fast-acting MDMA analogue	Animal study results for Parkinson's MDMA analogue	Identify lead drug candidates for Phase 1 trial	
3	Expand to Psilocybin & Ketamine Therapies	Develop ketamine assisted therapy protocol 	Begin treatment on first patient (ketamine)	Secure key approvals for psilocybin use	Begin treatment on first patient (psilocybin)
4	Unique CBD dose forms in Clinical Trials	Recommence Phase 3 trial of low-dose CBD for stress & anxiety	Begin Phase 1 trial of high-potency CBD treatments	Results of Phase 1 trial of high-potency CBD treatments	
5	Scale Clinical Health Services & Engage Payers	Secure a major payer partnership	Licence a care model to a clinical partner	Open a new clinic or form new clinical partnership	
6	Expand Intellectual Property & Build Partnerships	Receive Clear Search Report from international patent examiner	Secure granted patents in national phase	File new patent family provisionals	Updated commercial license with UWA

Australia is leading the charge globally in new treatments for mental health

The TGA's decision to legalise psychedelics, which came into force in July 2023, puts Emyria and Australia potentially years ahead of other jurisdictions like the US.

At the forefront of psychedelic assisted treatment

Emyria has the infrastructure (clinics and team) and approved care models needed to provide psychedelic treatments under TGA rules.

Novel MDMA analogue library

Emyria has partnered with UWA to develop a number of novel MDMA-like treatments.

The goal is to modify MDMA and unlock new therapeutics for neuropsychiatric disorders like Parkinson's disease.

Unparalleled access to patient data

Through our clinics, Emyria has access to opt-in patient data and uses a state-of-the-art data platform - Palantir Foundry - to reveal unique insights.

Clinics delivering revenue

Emyria provides wraparound, multidisciplinary mental health care services to patients.

We made \$1M last quarter (250% growth)

Unique CBD dose forms

Emyria is developing Ultra-Pure CBD for the treatment for anxiety symptoms and pain.

We have secured a commercial partner and are working with others, such as, the National Institutes of Health in the US to advance the program.

Experienced management team

Emyria's Board and Management are highly qualified in technology-backed clinical services, data and drug development.

A regulatory environment that advantages Emyria

Ready to be one of the first ASX companies providing these treatments

Strong IP covering unique potential medicines

Data that informs better care practices and drug development opportunities

Revenues subsidise R&D

Unique CBD products in clinical trials

Global leadership supports our global ambitions

CONTACT INFORMATION

Michael Winlo	mwinlo@emyria.com
Investors	investors@emyria.com
Media	media@emyria.com
General	info@emyria.com

INVESTOR HUB:

<https://investorhub.emyria.com/>

